Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Rapacuronium: clinical pharmacology.

R K Mirakhur¹, K C McCourt

¹Department of Anaesthetics and Intensive Care Medicine, Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK. r.mirakhur@qub.ac.uk

European Journal of Anaesthesiology. Supplement

|January 5, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a Core Outcome Set for studies evaluating the effects of anaesthesia on perioperative morbidity and mortality following hip fracture surgery.

British journal of anaesthesia·2018

Same author

Corrigendum to 'Perioperative outcomes in the context of mode of anaesthesia for patients undergoing hip fracture surgery: systematic review and meta-analysis' [Br J Anaesth 2018; 120: 37-50].

British journal of anaesthesia·2018

Same author

Perioperative outcomes in the context of mode of anaesthesia for patients undergoing hip fracture surgery: systematic review and meta-analysis.

British journal of anaesthesia·2018

Same author

Role of rocuronium and sugammadex in rapid sequence induction in pregnancy.

British journal of anaesthesia·2011

Same author

Sugammadex and rescue reversal.

Anaesthesia·2011

Same author

Management of neuromuscular block: time for a change?

Anaesthesia·2009

Same journal

EuroNeuro 2010. Abstracts of the 6th EuroNeuro Congress. Porto, Portugal. February 4-6, 2010.

European journal of anaesthesiology. Supplement·2010

Same journal

Euroanaesthesia 2003. Abstracts of the joint meeting of the European Society of Anaesthesiologists and European Academy of Anaesthesiology, Confederation of European National Societies of Anaesthesiology, and Association of Anaesthetists of Great Britain & Ireland. May 31-June 3, 2003. Glasgow, Scotland.

European journal of anaesthesiology. Supplement·2008

Same journal

Evoked potentials in the ICU.

European journal of anaesthesiology. Supplement·2008

Same journal

Intracranial pressure monitoring.

European journal of anaesthesiology. Supplement·2008

Same journal

Phrenic nerve stimulation.

European journal of anaesthesiology. Supplement·2008

Same journal

Direct stimulation: a useful technique.

European journal of anaesthesiology. Supplement·2008

See all related articles

Rapacuronium is a new neuromuscular blocking agent offering rapid action and short duration. However, serious pulmonary side effects and hemodynamic instability may limit its clinical use.

Area of Science:

Anesthesiology
Pharmacology

Background:

A need exists for rapid-acting, short-duration non-depolarizing neuromuscular blocking agents.
Rapacuronium was synthesized to meet this clinical demand.

Purpose of the Study:

To evaluate the efficacy and safety of rapacuronium as a neuromuscular blocking agent.

Main Methods:

Clinical trials assessing onset, duration, and intubating conditions.
Monitoring for adverse events including pulmonary and cardiovascular effects.

Main Results:

Rapacuronium demonstrated rapid onset (60-90 s) and short duration (15-30 min).
Provided acceptable intubating conditions, though inferior to succinylcholine in specific cases.
Significant dose-related pulmonary side effects (airway pressure, bronchospasm), hypotension, and tachycardia were observed.

Related Experiment Videos

Conclusions:

Rapacuronium offers rapid neuromuscular blockade but presents significant safety concerns.
Pulmonary and cardiovascular side effects may hinder its widespread clinical adoption.